House dust mite allergy vaccine - HAL Allergy
Alternative Names: Purethal MitesLatest Information Update: 15 Apr 2025
At a glance
- Originator HAL Allergy
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinitis; Allergic rhinoconjunctivitis
Most Recent Events
- 09 Sep 2024 Phase-III clinical trials in Allergic rhinitis in Bulgaria, Latvia, Lithuania, Poland and Germany (SC) (NCT06920771)
- 09 Sep 2024 Phase-III clinical trials in Allergic rhinoconjunctivitis in Lithuania, Poland, Poland, Latvia, Bulgaria and Germany (SC) (NCT06920771)
- 22 Mar 2022 No development reported - Phase-III for Allergic rhinitis in Slovakia, Portugal, Spain (SC) (HAL Allergy pipeline, March 2022)